Xiaojia Wang

Zhejiang Cancer Hospital - Department of Medical Oncology

China

SCHOLARLY PAPERS

2

DOWNLOADS

175

TOTAL CITATIONS

1

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Downloads 107 (556,470)
Citation 1

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Number of pages: 21 Posted: 12 Oct 2020
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu and The GAP Study Group
Fudan University - Department of Medical Oncology, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Breast Surgery, China Medical University - Department of Medical Oncology, Harbin Medical University - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Breast Cancer Center, Zhejiang Cancer Hospital - Department of Medical Oncology, Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Anhui Medical University - Department of Medical Oncology, Fudan University - School of Public Health, Department of Biostatics, Fudan University - Department of Breast Surgery, Fudan University - Department of Breast Surgery, Fudan University - Department of Radiation Oncology, Fudan University - Department of Medical Oncology and Independent
Downloads 54 (846,211)

Abstract:

Loading...

triple-negative breast cancer, chemotherapy, platinum, nab-paclitaxel

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

Number of pages: 21 Posted: 10 Nov 2020
Biyun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu and The GAP Study Group
Fudan University - Department of Medical Oncology, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Fudan University - Department of Medical Oncology, Fudan University - Department of Breast Surgery, China Medical University - Department of Medical Oncology, Harbin Medical University - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Breast Cancer Center, Zhejiang Cancer Hospital - Department of Medical Oncology, Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Anhui Medical University - Department of Medical Oncology, Fudan University - School of Public Health, Department of Biostatics, Fudan University - Department of Breast Surgery, Fudan University - Department of Breast Surgery, Fudan University - Department of Radiation Oncology, Fudan University - Department of Medical Oncology and Independent
Downloads 53 (854,333)
Citation 1

Abstract:

Loading...

metastatic triple-negative breast cancer, Chemotherapy, cisplatin, nab-paclitaxel

2.

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

Number of pages: 90 Posted: 05 Feb 2019
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning and Xianping Lu
Chinese PLA General Hospital - The Fifth Medical Center, Department of Medical Oncology, Jilin University (JLU) - First Affiliated Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Harbin Medical University - Cancer Hospital, Liaoning Cancer Hospital & Institute - Department of Medical Oncology, Zhengzhou University - Henan Cancer Hospital, Sun Yat-Sen University (SYSU) Cancer Center - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Jiangsu Province People's Hospital, Tumour Hospital of Hebei Province, Tianjin Medical University, Jilin Cancer Hospital, Anhui Medical University - Department of Medical Oncology, Shandong University - Jinan Central Hospital, Third Hospital of Nanchang, Beijing Cancer Hospital, Anhui Medical University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Institute of Cancer Research, Zhejiang Cancer Hospital - Department of Medical Oncology, Peking University - Shenzhen Hospital, Fudan University, Zhongshan Hospital, Department of Oncology, Cangzhou Central Hospital, Northwestern University - Feinberg School of Medicine, Chipscreen Biosciences Ltd and Chipscreen Biosciences Ltd
Downloads 68 (735,949)

Abstract:

Loading...

Chidamide; Histone deacetylase inhibitor; Exemestane; Hormonereceptor- positive; Advanced breast cancer; Phase 3 trial